Details

Autor(en) / Beteiligte

• Benson, Kevin
• McCrery, Rebecca
• Taylor, Chris
• Padron, Osvaldo
• Blok, Bertil
• Wachter, Stefan
• Pezzella, Andrea
• Gruenenfelder, Jennifer
• Pakzad, Mahreen
• Perrouin‐Verbe, Marie‐Aimee
• Van Kerrebroeck, Philip
• Mangel, Jeffrey
• Peters, Kenneth
• Kennelly, Michael
• Shapiro, Andrew
• Lee, Una
• Comiter, Craig
• Mueller, Margaret
• Goldman, Howard
• Lane, Felicia

Titel

One‐year outcomes of the ARTISAN‐SNM study with the Axonics System for the treatment of urinary urgency incontinence

Ist Teil von

• Neurourology and urodynamics, 2020-06, Vol.39 (5), p.1482-1488

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Aims Sacral neuromodulation (SNM) is a guideline‐recommended treatment for voiding dysfunction including urgency, urge incontinence, and nonobstructive retention as well as fecal incontinence. The Axonics® System is a miniaturized, rechargeable SNM system designed to provide therapy for at least 15 years, which is expected to significantly reduce revision surgeries as it will not require replacement as frequently as the non‐rechargeable SNM system. The ARTISAN‐SNM study is a pivotal study designed to treat patients with urinary urgency incontinence (UUI). Clinical results at 1‐year are presented. Methods A total of 129 eligible UUI patients were treated. All participants were implanted with a quadripolar tined lead and neurostimulator in a single procedure. Efficacy data were collected using a 3‐day bladder diary, a validated quality of life questionnaire (ICIQ‐OABqol), and a participant satisfaction questionnaire. Therapy responders were defined as participants with ≥50% reduction in UUI episodes compared to baseline. Data were analyzed on all 129 participants. Results At 1 year, 89% of the participants were therapy responders. The average UUI episodes per day reduced from 5.6 ± 0.3 at baseline to 1.4 ± 0.2. Participants experienced an overall clinically meaningful improvement of 34 points on the ICIQ‐OABqol questionnaire. All study participants (100%) were able to recharge their device at 1 year, and 96% of participants reported that the frequency and duration of recharging was acceptable. There were no serious device‐related adverse events. Conclusions The Axonics System is safe and effective at 1 year, with 89% of participants experiencing clinically and statistically significant improvements in UUI symptoms.